Article Text

Download PDFPDF
Systematic review
Allergen-specific immunotherapy improves asthma symptoms compared with placebo, but the possibility of adverse effects should be considered
  1. Rabia Rashid1,
  2. Anthony J Frew1
  1. 1Department of Allergy & Respiratory Medicine, Royal Sussex County Hospital, Brighton, UK
  1. Correspondence to Anthony J Frew
    Department of Allergy & Respiratory Medicine, Royal Sussex County Hospital, Brighton BN2 5BE UK; anthony.frew{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on:


Asthma affects millions of people worldwide. Current drug treatments for asthma relieve bronchospasm and airway inflammation but do not offer a cure, and symptoms return when treatment is stopped. In many parts of the world, allergen-specific immunotherapy is used to treat asthma; it is the only treatment option that targets the underlying disease process, by modulating the immune response. However, immunotherapy can induce severe adverse reactions including anaphylaxis and death, especially in people with asthma, which has led to restrictions on its use, particularly in the UK.1 In a previous systematic review, Abramson and colleagues2 included 75 trials of allergen immunotherapy in asthma published between 1954 and 2001. This review concluded that immunotherapy significantly reduced asthma symptoms, medication requirements and bronchial hypersensitivity. The authors have now updated their analysis, including 13 new trials published between 2001 and 2005.


The …

View Full Text


  • Competing interests None.